Enjuvia is a drug owned by Aspen Pharma Usa Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 08, 2021. Details of Enjuvia's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6660726 | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
Mar, 2021
(4 years ago) |
Expired
|
| US6855703 | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
Feb, 2021
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Enjuvia's patents.
Latest Legal Activities on Enjuvia's Patents
Given below is the list of recent legal activities going on the following patents of Enjuvia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 12 May, 2004 | US6660726 |
| Patent Issue Date Used in PTA Calculation
Critical | 09 Dec, 2003 | US6660726 |
| Recordation of Patent Grant Mailed
Critical | 09 Dec, 2003 | US6660726 |
| Issue Notification Mailed
Critical | 20 Nov, 2003 | US6660726 |
| Receipt into Pubs | 27 Oct, 2003 | US6660726 |
| Mail Response to 312 Amendment (PTO-271)
Critical | 23 Oct, 2003 | US6660726 |
| Application Is Considered Ready for Issue
Critical | 23 Oct, 2003 | US6660726 |
| Response to Amendment under Rule 312
Critical | 23 Oct, 2003 | US6660726 |
| Receipt into Pubs | 20 Oct, 2003 | US6660726 |
| Workflow - File Sent to Contractor | 25 Aug, 2003 | US6660726 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets
invalidated somehow, the
generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal
pitfalls. Given
below are details of the litigation history of Enjuvia and ongoing
litigations to
help you estimate the early arrival of Enjuvia generic.
Enjuvia's Litigations
Enjuvia been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 12, 2003, against patent number US6855703. The petitioner , challenged the validity of this patent, with Edward N Hill et al as the respondent. Click below to track the latest information on how companies are challenging Enjuvia's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6855703 | March, 2003 |
Decision
(11 Feb, 2004) | Edward N Hill et al | |
US patents provide insights into the exclusivity only within the United States, but
Enjuvia is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Enjuvia's family patents as well as insights into
ongoing legal events
on those patents.
Enjuvia's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Enjuvia's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 08, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Enjuvia Generics:
There are no approved generic versions for Enjuvia as of now.
Alternative Brands for Enjuvia
Enjuvia which is used for managing symptoms of menopause, including vaginal dryness, pain during intercourse, and vasomotor symptoms., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Apil |
| |||
| Duchesnay |
| |||
| Legacy Pharma |
| |||
| Wyeth Pharms |
| |||
About Enjuvia
Enjuvia is a drug owned by Aspen Pharma Usa Inc. It is used for managing symptoms of menopause, including vaginal dryness, pain during intercourse, and vasomotor symptoms. Enjuvia uses Estrogens, Conjugated Synthetic B as an active ingredient. Enjuvia was launched by Aspen in 2004.
Approval Date:
Enjuvia was approved by FDA for market use on 20 December, 2004.
Active Ingredient:
Enjuvia uses Estrogens, Conjugated Synthetic B as the active ingredient. Check out other Drugs and Companies using Estrogens, Conjugated Synthetic B ingredient
Treatment:
Enjuvia is used for managing symptoms of menopause, including vaginal dryness, pain during intercourse, and vasomotor symptoms.
Dosage:
Enjuvia is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.45MG | TABLET | Discontinued | ORAL |
| 1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 0.3MG | TABLET | Discontinued | ORAL |
| 0.9MG | TABLET | Discontinued | ORAL |
| 0.625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |